Genprex, Inc. (NASDAQ:GNPX) Sees Significant Growth in Short Interest

Genprex, Inc. (NASDAQ:GNPX) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 1,130,000 shares, a growth of 505.2% from the January 31st total of 186,700 shares. Based on an average trading volume of 920,700 shares, the days-to-cover ratio is presently 1.2 days. Currently, 13.7% of the shares of the company are short sold.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Geode Capital Management LLC raised its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 368.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 76,045 shares of the company’s stock after buying an additional 59,798 shares during the quarter. Geode Capital Management LLC owned about 0.89% of Genprex worth $65,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Stock Down 2.1 %

Shares of NASDAQ GNPX traded down $0.01 during midday trading on Friday, reaching $0.37. 211,868 shares of the stock traded hands, compared to its average volume of 1,011,194. Genprex has a one year low of $0.28 and a one year high of $5.41. The company’s 50 day moving average is $0.65 and its 200 day moving average is $0.86.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.